OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it has received an additional EUR 0.75 million from its co-development partner Biolex Therapeutics as part of its recently announced bridge financing.

OctoPlus N.V. ("OctoPlus") (Euronext: OCTO), the d

OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today the successful completion of the Phase IIa clinical study with its lead product Locteron(TM), a controlled release interferon alfa product for the treatment of chronic hepatitis C (HCV).

OctoPlus N.V. ("OctoPlus" or the "Company") (Euron

Biolex Therapeutics announced today that Company r